Loraz

Alcohol Withdrawal Delirium, Delirium, Panic Disorder + 12 more

Treatment

20 Active Studies for Loraz

What is Loraz

Lorazepam

The Generic name of this drug

Treatment Summary

Lorazepam is a type of benzodiazepine medication that is used to help reduce anxiety and sedate patients. It was developed in 1977 and approved by the FDA in 1985. It is a short-acting drug that is quickly cleared from the body.

Lorazepam

is the brand name

Loraz Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lorazepam

Lorazepam

1980

440

Effectiveness

How Loraz Affects Patients

Lorazepam works by increasing the frequency of opening of a chloride ion channel when it binds to certain receptors in the brain. This can have an anticonvulsant effect, meaning it can help prevent seizures. Lorazepam's effects may be compartmentalized, leading to different levels of sleepiness and dizziness.

How Loraz works in the body

Lorazepam attaches itself to special receptors in the brain that control GABA activity. When lorazepam binds to these receptors, it increases the flow of chloride ions into the cell. This causes the cell's membrane to become more stable, which can help reduce anxiety and seizures.

When to interrupt dosage

The recommended measure of Loraz is contingent upon the diagnosed illness, including Anxiety Disorders, Generalized Anxiety Disorder and Insomnia. Dosage also hinges on the method of delivery (e.g. Capsule, extended release - Oral or Liquid - Intramuscular; Intravenous) indicated in the table beneath.

Condition

Dosage

Administration

Depression

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Preoperative

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Catatonia

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Pharmacotherapy

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Status Epilepticus

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Insomnia

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Generalized Anxiety Disorder

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Anesthetic premedication therapy

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Anxiety Disorders

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Syndrome

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Agitation

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Panic Disorder

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Spasm

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Alcohol Withdrawal Delirium

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Delirium

0.5 mg, , 2.0 mg, 1.0 mg, 2.0 mg/mL, 4.0 mg/mL, 2.5 mg, 3.0 mg, 1.5 mg

, Oral, Tablet, Tablet - Oral, Liquid, Liquid - Oral, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Sublingual, Tablet - Sublingual, Solution, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Concentrate, Concentrate - Oral, Intramuscular, Injection - Intramuscular, Capsule, extended release, Capsule, extended release - Oral

Warnings

Loraz Contraindications

Condition

Risk Level

Notes

Obstructive Sleep Apnea (OSA)

Do Not Combine

Respiratory Insufficiency

Do Not Combine

Glaucoma

Do Not Combine

intra-arterial route of administration

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Lorazepam may interact with Pulse Frequency

There are 20 known major drug interactions with Loraz.

Common Loraz Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of sedation and somnolence can be increased when Lorazepam is combined with Deutetrabenazine.

Ethanol

Major

Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methadone

Major

Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Olanzapine

Major

The risk or severity of adverse effects can be increased when Lorazepam is combined with Olanzapine.

Loraz Toxicity & Overdose Risk

The toxic dose of lorazepam in mice is 1850mg/kg. An overdose may cause severe drowsiness, shallow breathing, coma, and death. Emergency medical treatment should be given to help eliminate the drug from the body. There is no evidence that lorazepam causes cancer or genetic damage. However, doses higher than 40mg/kg have been linked to increased fetal loss.

Loraz Novel Uses: Which Conditions Have a Clinical Trial Featuring Loraz?

1152 active clinical trials are currently assessing the potential of Lorazepam in providing relief from Anxiety Disorders, Generalized Anxiety Disorder and Insomnia.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Anxiety Disorders

55 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Preoperative

0 Actively Recruiting

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Anesthetic premedication therapy

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Panic Disorder

13 Actively Recruiting

Not Applicable

Alcohol Withdrawal Delirium

0 Actively Recruiting

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Delirium

26 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1

Catatonia

0 Actively Recruiting

Status Epilepticus

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Pharmacotherapy

1 Actively Recruiting

Not Applicable

Spasm

0 Actively Recruiting

Patient Q&A Section about loraz

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is lorazepam a pain killer?

"Lorazepam, marketed under the brand name Ativan among others, is a benzodiazepine medication. It is used to treat anxiety disorders, trouble sleeping, active seizures including status epilepticus, alcohol withdrawal, and chemotherapy-induced nausea and vomiting. Lorazepam has also been used in managing pain."

Answered by AI

What is lorazepam prescribed for?

"Lorazepam is a medication that is part of the class of drugs known as benzodiazepines. It is used to treat anxiety disorders and sleep problems that are related to anxiety. Lorazepam can be taken to help people relax before a medical procedure."

Answered by AI

What does taking lorazepam feel like?

"When I take a tablet, I start to feel myself relax.

Usually when I am having a panic attack, my muscles become tense and I feel like I can't breathe. Lorazepam helps alleviate those symptoms.

It works very fast, and I usually start to feel better 20 minutes after taking it."

Answered by AI

Is lorazepam a narcotic?

"Both lorazepam and opioids can be habit-forming, but they work differently.

Lorazepam is not an opioid and therefore not a narcotic."

Answered by AI

Clinical Trials for Loraz

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Acceptance and Commitment Therapy for Inflammatory Bowel Disease

18+
All Sexes
Houston, TX

Many Veterans with gastrointestinal disorders, such as inflammatory bowel disease (IBD), also have mental health conditions. IBD and mental health conditions can worsen one another through the brain-gut axis, leading to dramatic deficits in psychosocial functioning and quality of life (QOL). Yet, few Veterans with comorbid IBD and mental health conditions receive psychotherapy and no evidence-based psychotherapies have been tested in Veterans with these comorbidities. Adapting brief acceptance and commitment therapy (ACT) to the specific to the needs of these patients and embedding treatment into routine gastroenterology care may increase Veterans' access to efficient and effective rehabilitative care. This study aims to adapt and test an integrated, 1-Day ACT intervention tailored to the specific needs of Veterans with IBD and mental health conditions to improve psychosocial functioning and QOL.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Mackenzie Lynmarie Shanahan, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Loraz clinical trials?

We made a collection of clinical trials featuring Loraz, we think they might fit your search criteria.
Go to Trials
Image of Liao Lab at UCSF in San Francisco, United States.

Audio-Based Therapy for Anxiety in Psoriasis

18+
All Sexes
San Francisco, CA

Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.

Waitlist Available
Behavior

Liao Lab at UCSF

Wilson Liao, MD

Image of University of Rochester Medical Center in Rochester, United States.

Medical Cannabis for Nausea and Vomiting

18+
All Sexes
Rochester, NY

Many people receiving chemotherapy experience nausea despite standard anti-nausea medications. Medical cannabis is commonly used to help manage nausea, but there is limited scientific evidence about its effectiveness when used alongside modern chemotherapy treatments. This study will evaluate whether medical cannabis can reduce nausea in adults receiving moderately or highly nausea-causing chemotherapy. Participants will be randomly assigned to start medical cannabis either immediately or after one chemotherapy cycle, allowing comparison of symptoms with and without cannabis use. All participants will continue their usual anti-nausea medications. The study will also examine effects on vomiting, appetite, pain, fatigue, sleep, mood, quality of life, and inflammation. Results from this pilot study will help determine the safety, feasibility, and potential benefits of medical cannabis for chemotherapy-related nausea and guide future larger clinical trials.

Phase 2
Waitlist Available

University of Rochester Medical Center

Have you considered Loraz clinical trials?

We made a collection of clinical trials featuring Loraz, we think they might fit your search criteria.
Go to Trials
Image of San Luis Obispo County Juvenile Hall in San Luis Obispo, United States.

Multi-Sensory Therapy for Emotional Dysregulation

12 - 18
All Sexes
San Luis Obispo, CA

Emotional dysregulation in justice-involved youth (JIY) is a condition that significantly impacts young people, their families, and juvenile justice and public health systems. Affecting an estimated 60-70% of detained Attention deficit hyperactivity disorderadolescents, it is a major driver of aggression, substance use, school failure, and later recidivism. Despite available treatments, managing emotional dysregulation in custody remains challenging, with youth often enduring high arousal, anger, and anxiety that persist into adulthood. Current popular therapies, including Cognitive Behavioral Therapy (CBT) and Dialectic Behavioral Therapy (DBT), often fall short in detention because they rely on verbal processing, require multiple scheduled sessions, and/or need highly trained staff. Other technologies, like biofeedback and neurostimulation techniques, are still under scrutiny for adolescents, given their higher-than-usual Adverse Events (AEs). This SoundHeal study aims to evaluate a sensory intervention using the Healpod, a distraction-free physical space where a participant sits, delivering sound, music, gentle vibrations, and ambient light. Following this is a brief expressive journaling exercise to compare any before, during and after experience changes from the sensory immersion. This prospective, single-center cohort study hypothesizes that these sessions will improve juveniles' ability to emotionally regulate, improve therapeutic alliance, mental health outcomes and build coping skills that can potentially help in long-term mental health and substance abuse treatment in JIY and beyond.

Recruiting
Has No Placebo

San Luis Obispo County Juvenile Hall

Nishat Bhuiyan, PhD

SoundHeal

Image of University of South Florida in Tampa, United States.

Web-Based Program for Parenting Stress

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to evaluate the feasibility, usability, and preliminary benefits of implementing ACT Together for parents of children with disabilities in pediatric outpatient clinics. ACT Together includes six self-paced, web-based modules and brief weekly one-on-one coaching sessions led by a trained occupational therapist. The program is based on acceptance and commitment therapy (ACT), which teaches practical skills to help people handle stress and difficult thoughts or feelings while taking steps toward what matters to them. The main questions this study aims to answer are: * Can parents and occupational therapists complete the study activities as planned (e.g., module completion, coaching sessions, and surveys)? * Is the program usable and acceptable/appropriate/feasible to implement in this setting? * Do parents show improvements in mental health and coping-related outcomes after participating in the program? * What are the experiences and perspectives of parents and therapists regarding the program? Parents as participants will: * Complete six self-paced web-based modules and brief weekly individual coaching sessions with a trained occupational therapist. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experiences and perspectives on the program. Occupational therapists as participants will: * Complete therapist training materials and deliver brief individual coaching sessions to parent participants, including completing a post-session checklist. * Complete brief online questionnaires before starting and after delivering the program. * Take part in one online interview about their experiences and perspectives on the program.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han, PhD

Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Loraz clinical trials?

We made a collection of clinical trials featuring Loraz, we think they might fit your search criteria.
Go to Trials